Increased arterial compliance in cirrhosis is related to decreased arterial C-type natriuretic peptide, but not to atrial natriuretic peptide

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 5, 2003, Pages 559-564

  Henriksen, Jens H ^a   Gulberg V ^b   Gerbes, A L ^b   Bendtsen, F ^b   Moller S ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

Arterial compliance; Arterial mechanics; Atrial natriuretic peptide (ANP); C type natriuretic peptide (CNP); Circulatory dysfunction in cirrhosis; Vascular reactivity; Vasodilators

Indexed keywords

ATRIAL NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C;

ADULT; AGED; ARTERIAL PRESSURE; ARTERY COMPLIANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART OUTPUT; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYSTEMIC VASCULAR RESISTANCE;

ADULT; AGED; ARTERIES; ATRIAL NATRIURETIC FACTOR; DILATATION, PATHOLOGIC; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, C-TYPE; VASCULAR DISEASES;

EID: 0037613295     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310000393     Document Type: Article

References (44)

1. Kiszka-Kanowitz M, Henriksen JH, Møller S, Bendtsen F. Blood volume distribution in patients with cirrhosis:aspects of the dual-head gamma-camera technique. J Hepatol 2001;35:605-12.
2. Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997;17:505-19.
3. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000;32:157-70.
4. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann RJ, editors. Portal hypertension. Pathophysiology and treatment. Oxford: Blackwell; 1994. p. 17-26.
5. Bernardi M, Fornale L, Dimarco C, Trevisani F, Baraldini M, Gasbarrini A, et al. Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol 1995;22:309-18.
6. Martin PY, Gines P, Schrier RW. Mechanisms of disease: nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339:533-41.
7. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;5:1151-7.
8. Sherlock S. Vasodilatation associated with hepatocellular disease: relation to functional organ failure. Gut 1990;31:365-7.
9. Møller S, Henriksen JH. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998;58:361-72.
10. Bandi JC, Fernandez M, Bernadich C, de Lacy AM, Garcia-Pagan JC, Bosch J, et al. Hyperkinetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of chronic nitric oxide inhibition. J Hepatol 1999;31:719-24.
11. Henriksen JH, Schütten HJ, Bendtsen F, Warberg J. Circulating atrial natriuretic peptide (ANP) and central blood volume (CBV) in cirrhosis. Liver 1986;6:361-8.
12. Panos MZ, Anderson JV, Payne N, Langley P, Slater JDH, Rees L, et al. Plasma atrial natriuretic peptide and renin-aldosterone in patients with cirrhosis and ascites: basal levels, changes during daily activity and nocturnal diuresis. Hepatology 1992;16:82-8.
13. Henriksen JH, Bendtsen F, Gerbes AL, Christensen NJ, Ring-Larsen H, Sørensen TIA. Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992;16:1163-70.
14. Bendtsen F, Gerbes AL, Henriksen JH. Disposal of atrial natriuretic factor (ANF 99-126) in patients with cirrhosis: effect and beta-adrenergic blockade. Scand J Clin Invest 1993;53:547-54.
15. Gerbes AL, Wernze H, Arendt RM, Riedl A, Sauerbruch T, Paumgartner G. Atrial natriuretic factor and renin - aldosterone in volume regulation of patients with cirrhosis. Hepatology 1989;9:417-22.
16. Gülberg V, Møller S, Henriksen JH, Gerbes AL. Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut 2000;47:852-7.
17. Gerbes AL. The role of atrial natriuretic peptide (ANP) in chronic liver disease. Pharmacol Ther 1993;58:381-90.
18. Wei CM, Aarhus LL, Miller VM, Burnett JC. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol 1993;264:H71-3.
19. Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. Lancet 1997;349:1307-10.
20. Bomzon A, Blendis LM. Vascular reactivity in experimental portal hypertension. Am J Physiol 1987;252:G158-62.
21. MacGilchrist AJ, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. Hepatology 1991;13:689-94.
22. Ryan J, Sudhir K, Jennings G, Esler M, Dudley F. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993;105:1167-72.
23. Gentilini P, Romanelli RG, Laffi G, Barletta G, Delbene R, Messeri G, et al. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. J Hepatol 1999;30:632-8.
24. Henriksen JH, Møller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. J Hepatol 1999;31:712-8.
25. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20:51-9.
26. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Arterial compliance in patients with cirrhosis. High stroke volume/pulse pressure ratio as an index of elevated arterial compliance. Am J Physiol 2001;280:G584-94.
27. Henriksen JH, Møller S, Schifter S, Abrahamsen J, Becker U. High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene-related peptide (CGRP), but not to activated vasoconstrictor systems. Gut 2001;49:112-8.
28. Sherlock S, Dooley J. Diseases of the liver and biliary system. Oxford: Blackwell; 1993.
29. Gluud C, The Copenhagen Study Group for Liver Diseases, Serum testosterone concentration in men with alcoholic cirrhosis: background for variation. Metabolism 1987;36:373-8.
30. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995;109:1917-25.
31. Møller S, Wiinberg N, Henriksen JH. Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology 1995;22:88-95.
32. Møller S, Christensen E, Henriksen JH. Continuous blood pressure monitoring in cirrhosis: relations to splanchnic and systemic haemodynamics. J Hepatol 1997;27:284-94.
33. Møller S, Gülberg V, Becker U, Gerbes AL, Henriksen JH. Elevated arterial compliance in patients with cirrhosis is not related to arterial endothelin-1. Scand J Gastroenterol 2002;37:1064-9.
34. Gerbes AL, Wernze H, Arendt RM, Riedel A, Sauerbruch T, Paumgartner G. Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. Hepatology 1989;9:417-22.
35. Henriksen JH, Bendtsen F, Gerbes AL. Splanchnic removal of human alpha-atrial natriuretic peptide in humans: enhancement after food intake. Metabolism 1990;39:553-6.
36. Salo J, Gines A, Anibarro L, Jimenez W, Bataller R, Claria J, et al. Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology 1995;22:479-87.
37. Trevisani F, Colantoni A, Sica G, Gasbarrini A, Dintino PE, Denotariis S, et al. High plasma levels of atrial natriuretic peptide in preascitic cirrhosis: indirect evidence of reduced natriuretic effectiveness of the peptide. Hepatology 1995;22:132-7.
38. Macaulay Hunter EF, Kelly PA, Prowse C, Woods RJ, Lowry PJ. Analysis of peptides derived from Pro Atrial Natriuretic Peptide that circulates in man and increase in heart disease. Scand J Clin Lab Invest 1998;58:205-16.
39. Gadano A, Moreau R, Vachiery F, Soupison T, Yang S, Cailmail S, et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997;26:1229-34.
40. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235-9.
41. Pizcueta P, Pique JM, Fernandez M, Bosch J, Rodes J, Whittle BJR, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992;103:1909-15.
42. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994;20:1343-50.
43. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122:85-93.
44. Henriksen JH, Ring-Larsen H, Kanstrup I-L, Christensen NJ. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis. Gut 1984;25:1034-43.